Welcome to our dedicated page for Ufp Technologies SEC filings (Ticker: UFPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UFP Technologies Inc. filings document operating results and material events for its medical-device contract development and manufacturing business. Form 8-K reports furnish quarterly and annual earnings releases, non-GAAP financial measures, Regulation FD investor presentation materials, material definitive agreements with strategic medical customers, cybersecurity incident disclosures, and executive succession and compensation arrangements.
Proxy filings cover board elections, executive compensation, equity awards, pay-versus-performance disclosure, and shareholder voting matters. These records frame the company's governance, capital and incentive structure, customer-contract disclosures, and public reporting obligations as a Nasdaq-listed operating company.
Daniel C. Croteau, a director of UFP Technologies, acquired 1,318 shares of common stock on 08/07/2025 at a reported price of $22.36 per share, increasing his direct beneficial ownership to 3,728 shares. The transaction corresponds to the exercise of a stock option with a $22.36 exercise price originally exercisable on 12/16/2015 and expiring on 12/16/2025. The Form 4 was signed by an attorney-in-fact on 08/14/2025.
UFP Technologies reported significant revenue and profit growth driven largely by recent acquisitions while facing margin pressure, higher interest expense, and customer concentration.
Net sales were $151.2 million for the quarter (up 37.2% year-over-year) and $299.3 million for the six months (up 39.1%). Net income was $17.2 million in the quarter and $34.4 million year-to-date, with diluted EPS of $2.21 for the quarter and $4.42 for six months. Gross margin declined to 28.8% in Q2 from 30.0% due to higher material, labor and onboarding inefficiencies at newly acquired AJR operations. SG&A rose in absolute dollars but decreased as a percentage of sales to 12.4% in Q2.
The company completed multiple acquisitions that expanded its medical-market capabilities and geography, including AJR Enterprises ($110.7M), AQF ($47.7M), Welch ($35.2M), Marble ($5.0M) and AJR Specialty ($2.8M); these collectively contributed about $76.3M in sales in H1 2025. Long-term debt outstanding was $163.6 million with Q2 interest expense of $2.7 million; cash from operations was $39.1 million for six months. Management disclosed contingent consideration obligations, tariff exposure estimated at ~$9 million annually, and customer concentration with two customers representing ~27.4% and ~20.3% of Q2 sales.